359 related articles for article (PubMed ID: 17509920)
1. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.
McEachern KA; Fung J; Komarnitsky S; Siegel CS; Chuang WL; Hutto E; Shayman JA; Grabowski GA; Aerts JM; Cheng SH; Copeland DP; Marshall J
Mol Genet Metab; 2007 Jul; 91(3):259-67. PubMed ID: 17509920
[TBL] [Abstract][Full Text] [Related]
2. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.
Marshall J; McEachern KA; Chuang WL; Hutto E; Siegel CS; Shayman JA; Grabowski GA; Scheule RK; Copeland DP; Cheng SH
J Inherit Metab Dis; 2010 Jun; 33(3):281-9. PubMed ID: 20336375
[TBL] [Abstract][Full Text] [Related]
3. Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice.
Nietupski JB; Pacheco JJ; Chuang WL; Maratea K; Li L; Foley J; Ashe KM; Cooper CG; Aerts JM; Copeland DP; Scheule RK; Cheng SH; Marshall J
Mol Genet Metab; 2012 Apr; 105(4):621-8. PubMed ID: 22366055
[TBL] [Abstract][Full Text] [Related]
4. Substrate reduction therapy using Genz-667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of Gaucher disease.
Blumenreich S; Yaacobi C; Vardi A; Barav OB; Vitner EB; Park H; Wang B; Cheng SH; Sardi SP; Futerman AH
J Neurochem; 2021 Mar; 156(5):692-701. PubMed ID: 32743826
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.
Barnes S; Xu YH; Zhang W; Liou B; Setchell KD; Bao L; Grabowski GA; Sun Y
PLoS One; 2014; 9(12):e116023. PubMed ID: 25551612
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy.
Pavlova EV; Archer J; Wang S; Dekker N; Aerts JM; Karlsson S; Cox TM
J Pathol; 2015 Jan; 235(1):113-24. PubMed ID: 25256118
[TBL] [Abstract][Full Text] [Related]
7. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
Pandey MK; Burrow TA; Rani R; Martin LJ; Witte D; Setchell KD; Mckay MA; Magnusen AF; Zhang W; Liou B; Köhl J; Grabowski GA
Nature; 2017 Mar; 543(7643):108-112. PubMed ID: 28225753
[TBL] [Abstract][Full Text] [Related]
8. Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases.
Cox TM
Curr Opin Investig Drugs; 2010 Oct; 11(10):1169-81. PubMed ID: 20872320
[TBL] [Abstract][Full Text] [Related]
9. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.
Moyses C
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):955-60. PubMed ID: 12803929
[TBL] [Abstract][Full Text] [Related]
10. AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease.
McEachern KA; Nietupski JB; Chuang WL; Armentano D; Johnson J; Hutto E; Grabowski GA; Cheng SH; Marshall J
J Gene Med; 2006 Jun; 8(6):719-29. PubMed ID: 16528760
[TBL] [Abstract][Full Text] [Related]
11. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.
Bennett LL; Turcotte K
Drug Des Devel Ther; 2015; 9():4639-47. PubMed ID: 26345314
[TBL] [Abstract][Full Text] [Related]
12. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.
Belmatoug N; Di Rocco M; Fraga C; Giraldo P; Hughes D; Lukina E; Maison-Blanche P; Merkel M; Niederau C; Plӧckinger U; Richter J; Stulnig TM; Vom Dahl S; Cox TM
Eur J Intern Med; 2017 Jan; 37():25-32. PubMed ID: 27522145
[TBL] [Abstract][Full Text] [Related]
13. CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.
Marshall J; Sun Y; Bangari DS; Budman E; Park H; Nietupski JB; Allaire A; Cromwell MA; Wang B; Grabowski GA; Leonard JP; Cheng SH
Mol Ther; 2016 Jun; 24(6):1019-1029. PubMed ID: 26948439
[TBL] [Abstract][Full Text] [Related]
14. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
[TBL] [Abstract][Full Text] [Related]
15. Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration.
Farfel-Becker T; Vitner EB; Kelly SL; Bame JR; Duan J; Shinder V; Merrill AH; Dobrenis K; Futerman AH
Hum Mol Genet; 2014 Feb; 23(4):843-54. PubMed ID: 24064337
[TBL] [Abstract][Full Text] [Related]
16. A new brain-penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher disease.
Fujii T; Tanaka Y; Oki H; Sato S; Shibata S; Maru T; Tanaka Y; Tanaka M; Onishi T
J Neurochem; 2021 Nov; 159(3):543-553. PubMed ID: 34398463
[TBL] [Abstract][Full Text] [Related]
17. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage.
Mizukami H; Mi Y; Wada R; Kono M; Yamashita T; Liu Y; Werth N; Sandhoff R; Sandhoff K; Proia RL
J Clin Invest; 2002 May; 109(9):1215-21. PubMed ID: 11994410
[TBL] [Abstract][Full Text] [Related]
18. [Molecular basis of treatment in Gaucher's disease].
Pocoví M
Med Clin (Barc); 2011 Sep; 137 Suppl 1():32-8. PubMed ID: 22230123
[TBL] [Abstract][Full Text] [Related]
19. Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease.
Schueler UH; Kolter T; Kaneski CR; Zirzow GC; Sandhoff K; Brady RO
J Inherit Metab Dis; 2004; 27(5):649-58. PubMed ID: 15669681
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of Glucosylceramide Synthase.
Shayman JA; Hinkovska-Galcheva V; Shu L
Methods Mol Biol; 2023; 2613():271-288. PubMed ID: 36587085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]